Neurocrine Biosciences (NBIX)
(Real Time Quote from BATS)
$147.59 USD
+3.46 (2.40%)
Updated Aug 8, 2024 09:52 AM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 42% (105 out of 250)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.46 | 1.52 | 9.99 |
Current Quarter Estimate | 1.48 | -2.04 | 61.00 |
Year Ago Quarter Estimate | 0.82 | -0.59 | 54.84 |
Next Quarter Estimate | 1.61 | -2.00 | 63.00 |
Next Year Estimate | 7.07 | 6.92 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 69.64 | 15.10 | 15.67 |
Next Year | 68.74 | 16.30 | 11.34 |
Last 5 Years | 59.90 | 7.00 | 8.10 |
Next 5 Years | NA | 24.60 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 43.54 | -5.88 |
Price/Book (MRQ) | 5.80 | 1.58 |
Price/Cash Flow (MRFY) | 55.88 | 8.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 16.00% | 6.02% |
Return on Equity (TTM) | 14.86% | 7.75% |
Debt to Equity (MRQ) | 0.00 | 2.23 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.